'Clinical phase' presentation slideshows

705 views • 58 slides

Screening in Disease Detection

Screening in Disease Detection. Natural history of disease. Onset of symptoms. Usual time of diagnosis. Exposure. Pathologic changes. Stage of subclinical disease. Stage of recovery, disability or death. Stage of clinical disease. Stage of susceptibility. PRIMARY PREVENTION.

805 views • 54 slides

Nematic protein organisation technology:

1.4k views • 46 slides

909 views • 42 slides

The Future of Basic Sciences in Undergraduate Medical Education

The Future of Basic Sciences in Undergraduate Medical Education. Douglas L. Wood, D.O., Ph.D. President - AACOM. Will Discuss. 1. Current Status of undergraduate medical education 2. Future status of undergraduate medical education - The role of the basic sciences in that future.

645 views • 41 slides

Hope in the Pipeline I Development of Drugs to Treat TB

Hope in the Pipeline I Development of Drugs to Treat TB. IUALTD 2011 - J2J Symposium Daniel Everitt, MD TB Alliance. Development of Drugs to Treat TB Outline of Discussion. Current and historic regimens to treat TB Treatment needs for the future and our historic opportunity

607 views • 40 slides

RENAL DISEASE IN DIABETES

RENAL DISEASE IN DIABETES. Diabetic Symposium 24th May 2006. Dr Nick Fluck Consultant Nephrologist Aberdeen Royal Infirmary. Diabetic Nephropathy. The Natural History of Diabetic Nephropathy Epidemiology Chronic Kidney Disease Preventing Progression of Diabetic Nephropathy

925 views • 38 slides

EPI-820 Evidence-Based Medicine

EPI-820 Evidence-Based Medicine. LECTURE 5: SCREENING Mat Reeves BVSc, PhD. Objectives. Two components of screening (Dx & Tx). Determinants of pre-clinical phase Concept of lead time Characteristics of screening tests (Se, Sp, yield) Biases - lead time, selection, length-biased

469 views • 35 slides

Stephen T. Parente, Ph.D. $ $ Carlson School of Management, Department of Finance

University of Minnesota Medical Technology Evaluation and Market Research Department of Healthcare Management Course: MILI/PUBH 6589 Spring Semester, 2012. Stephen T. Parente, Ph.D. $ $ Carlson School of Management, Department of Finance.

484 views • 34 slides

MOVING NOVEL CONCEPTS FROM RESEARCH LABORATORY TO CLINICAL PROOF-OF-PRINCIPLE

MOVING NOVEL CONCEPTS FROM RESEARCH LABORATORY TO CLINICAL PROOF-OF-PRINCIPLE. BIOPHARMACEUTICAL DEVELOPMENT PROGRAM BIOLOGICAL RESOURCES BRANCH DEVELOPMENTAL THERAPEUTICS PROGRAM NATIONAL CANCER INSTITUTE FREDERICK, MARYLAND. Mission.

516 views • 27 slides

Dosage Determination from Preclinical to Proof-of-Concept Trials, (Including Toxicology)

Dosage Determination from Preclinical to Proof-of-Concept Trials, (Including Toxicology). Charlie Taylor, PhD CpTaylor Consulting Chelsea, MI, USA. Choosing Doses for POC:. Preclinical and early studies that enable dose selection Reasons for drug failure in clinical phase 2-3

791 views • 23 slides

Working Group on TB Drugs

Working Group on TB Drugs. Developing A Faster Cure. Maria C. Freire, Ph.D. Chair. Working Group Coordination. Treatment Today. Treatment Tomorrow. DOTS-Plus MDR-TB. New TB Vaccines. HIV/TB. DOTS Expansion. New TB Drugs. New TB Diagnostics. Mission.

354 views • 23 slides

Handling Complex Decisions in the Development of New Drugs in Pharmaceutical Firms

Handling Complex Decisions in the Development of New Drugs in Pharmaceutical Firms. Cassimon, Engelen and Yordanov. FUR XII , LUISS, Roma , Italy, 22-26 June 2006. Valuation of pharma companies.

328 views • 19 slides

Handling Complex Decisions in the Development of New Drugs in Pharmaceutical Firms

Handling Complex Decisions in the Development of New Drugs in Pharmaceutical Firms. Cassimon, Engelen and Yordanov. FUR XII , LUISS, Roma , Italy, 22-26 June 2006. Valuation of pharma companies.

327 views • 19 slides

Immunotherapy Against Metastasis

Immunotherapy Against Metastasis. Entering phase IIb placebo-controlled study in 2019. Safe Harbour Statement.

377 views • 17 slides

175 views • 6 slides